Drug intelligence / Profile preview

trastuzumab + taxane

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of trastuzumab (Herceptin), a HER2-targeted monoclonal antibody, and a taxane chemotherapy agent (either paclitaxel/Taxol or docetaxel/Taxotere). This regimen is primarily used for treating HER2-positive breast cancer. Trastuzumab works by binding to HER2 receptors on cancer cells, blocking signals that cause cell proliferation, while taxanes damage the cellular structure that supports cancer cell division. The combination shows synergistic effects, with docetaxel demonstrating direct NK Group 2 member D receptor upregulation that enhances trastuzumab's antibody-dependent cellular cytotoxicity.

Other names: TH regimenTH chemotherapy regimen

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on trastuzumab + taxane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on trastuzumab + taxane.

Explore the full profile